Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Decitabine enhances the cytotoxic effect of ruxolitinib in myeloproliferative neoplasms by targeting SR splicing factors

View Full Paper
Ask AI
Bookmark
Share

Authors

QHQingmei HanRLRumeng LiBWBingbing Wen

Discussion

Loading...

Member takes

Overview

Combination therapy improves cytotoxic effect and apoptosis in hematological malignancies, suggesting new treatment routes.

Key Points

  • To evaluate the impact of decitabine on the efficacy of ruxolitinib in treating myeloproliferative neoplasms.
  • Used SET-2 and HEL cell lines for in vitro analysis
  • Conducted colony formation, apoptosis, and cell viability assays
  • Utilized Western Blot and RT-qPCR for protein and gene expression analysis
  • Employed a xenograft murine model for in vivo experiments
  • Combination treatment significantly reduced cell viability compared to monotherapy
  • Enhanced apoptosis observed with combined therapy
  • Significantly reduced tumor burden in xenograft model
  • SRSF1 and SRSF2 expression levels decreased with combination treatment

Cite This Study

Han et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d91bhttps://doi.org/10.1182/blood-2025-7276
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preclinical efficacy of the synergistic Ruxolitinib–Homoharringtonine combination in TP53-mutated myeloproliferative neoplasms progressing to sAML2025
  2. 2Abstract 7225: Combination JAK1/2 and CDK8/19 inhibition demonstrates enhanced efficacy in myeloproliferative neoplasms2024
  3. 3Ruxolitinib and decitabine plus a busulfan–cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes2025
  4. 4Abstract 564: Therapeutic targeting of JAK/STAT signaling and histone acetyltransferase activity in post-myeloproliferative neoplasm secondary AML2024
  5. 5Genome-wide CRISPR-Cas9 screen reveals novel ruxolitinib-resistance targets in myeloproliferative neoplasms2025